Oncolytic virus · Kills target cells · developed by JOHNSON & JOHNSON
JNJ-87704916 is a recombinant oncolytic herpes simplex virus type 1 that is given by intratumoral injection. It preferentially infects and replicates in tumor cells, causing their lysis, and the released tumor antigens are reported to induce a tumor-specific cytotoxic T-lymphocyte response against nearby tumor cells. It is studied in neoplasms.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06311578 | Phase 1 | Neoplasms | Recruiting | JNJ |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Neoplasms
Updated Oct 18, 2026. Something wrong or missing? Report it on the JNJ page.
See JNJ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
JNJ catalysts and pipeline →